Bio-Rad Laboratories, Inc. (BIO) Down 5.7% — Should I Turn This Into Liquidity?
Bio-Rad Laboratories, Inc. (BIO) is under sharp pressure on Thursday, last changing hands at $356.25 on the NYSE. That is a $23.30 decline from the prior close of $379.55. The drop erases a large share of the late-summer advance that carried the stock to its 52-week high of $396.23 on August 27, 2026. BIO now sits roughly 10.1% below that peak, and a stock that was pressing toward new highs barely a month ago has given back much of that ground in a single session.
Volume is running light so far, with about 134,465 shares traded against a 90-day average of roughly 310,337. That puts turnover at about 43% of a typical full session while the regular session is still open.
Why Bio-Rad Laboratories, Inc. Price is Moving Lower
The clearest driver is a broad selloff in life science tools names. Bio-Rad's closest peers are falling hard alongside it. Danaher Corporation (DHR) is down 3.96% and Thermo Fisher Scientific Inc. is off 2.80% (TMO). The large-cap pharmaceutical names are holding up far better, with Merck & Co., Inc. (MRK) down 1.39% and Gilead Sciences, Inc. (GILD) down 0.93%. That split points to selling aimed at research-tools and instrument suppliers rather than at Health Care sector as a whole. Bio-Rad is a smaller company with heavy exposure to academic and biopharma research budgets, so it tends to move further than its larger peers when sentiment toward the group sours. Today's 5.68% drop fits that pattern.
The fundamental backdrop explains why investors are quick to sell when the group weakens. Bio-Rad's Q2 results, released on August 4, looked strong on the surface. Adjusted EPS of $2.62 beat the $1.81 consensus, and revenue of $651 million topped the $623.89 million estimate. But sales were essentially flat year over year and declined 1.9% on a currency-neutral basis. Life Science sales fell 4.1% as reported, reflecting weak academic research demand. Management reaffirmed 2026 currency-neutral revenue guidance of -3.0% to +0.5%, a range that leaves open the possibility of a full-year decline.
Valuation adds to the sensitivity. BIO trades at a forward P/E of 46.03, a demanding multiple for a business whose top line is shrinking slightly, at -0.09%. On September 28, RBC reiterated its Outperform rating and $390 price target, citing an expected sales recovery and margin improvement in 2027. That case rests on a rebound that has not yet appeared in the reported numbers. When peers sell off, a stock priced on next year's recovery has little support from current results.
What is the Bio-Rad Laboratories, Inc. Rating - Should I Sell?
Weiss Ratings assigns BIO a C- rating. Current recommendation is Hold. The C- sits at the low end of the Hold range. Bio-Rad's balance sheet keeps it out of Sell territory, but the earnings power and the stock's behavior give little reason to rate it higher.
The strongest part of the profile is the Excellent rating on the Solvency Index. That rating matters for a company facing a soft demand cycle. With academic research spending weak and Life Science sales contracting, Bio-Rad's financial footing gives it room to wait for the 2027 recovery analysts are expecting. It does not need to cut investment or take on balance-sheet risk to get there.
The operating side is more mixed. The Fair rating on the Growth Index reflects a business that is standing still. Revenue growth of -0.09% and a currency-neutral decline of 1.9% in the latest quarter show the top line has stalled rather than collapsed. The Efficiency Index is also rated Fair. A 3.11% ROE is thin for a company with Bio-Rad's market position in research instruments and diagnostics, and an 8.58% profit margin shows how little of its revenue reaches shareholders right now. The Total Return Index is rated Fair as well. The run to $396.23 in August rewarded holders, but today's drop has reversed a large part of that gain. The Weak Volatility Index is easy to understand on a day like this one. Bio-Rad is falling roughly twice as far as Danaher and Thermo Fisher in the same tools-sector selloff, and that kind of amplified move is why the rating is not higher.
Within the Health Care sector, Bio-Rad trails Thermo Fisher Scientific Inc. (TMO, C+), Danaher Corporation (DHR, C), and Merck & Co., Inc. (MRK, C). Its closest competitors carry better risk/reward profiles in the Weiss framework, which makes a cautious stance more reasonable than adding to positions.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) is a Health Care company in the Pharmaceuticals, Biotechnology and Life Sciences industry. Founded in 1952 and headquartered in Hercules, California, the company develops, makes, and sells instruments, reagents, and software through two main businesses: Life Science and Clinical Diagnostics. Its customers include universities, government research institutes, biopharmaceutical companies, hospital and reference laboratories, and blood banks around the world.
The Life Science segment supplies tools used to separate, identify, and measure biological material. Its flagship platform is Droplet Digital PCR, sold as the QX family of ddPCR systems, which are used in oncology research, cell and gene therapy development, and biopharma quality control. The segment also sells CFX real-time PCR systems, Mini-PROTEAN and Criterion electrophoresis products, ChemiDoc imaging systems, and Bio-Plex multiplex immunoassays. Its process chromatography resins are used in biologic drug manufacturing. Because much of this business depends on academic and government research budgets, it has been the main source of recent weakness.
The Clinical Diagnostics segment provides a steadier revenue base. Bio-Rad is a leading supplier of laboratory quality control materials, supported by its Unity data management software, which labs use to monitor test accuracy. The segment also offers the BioPlex 2200 system for autoimmune and infectious disease testing, D-10 and Variant II systems for hemoglobin and diabetes monitoring, and the IH-series instruments for blood typing and immunohematology. Bio-Rad's main competitive advantages are its large installed base of instruments, recurring consumables revenue, and long-standing relationships with clinical labs. These strengths are difficult for newer competitors to replace, but they do not shield the company from cycles in research spending.
Investor Outlook
Bio-Rad Laboratories, Inc. (BIO) carries a Weiss Rating of C- (Hold). A shrinking top line, a 46.03 forward P/E, and strong sensitivity to swings in the life science tools group argue for patience over accumulation. Investors should watch whether Life Science sales stabilize as academic demand recovers, and whether the company finishes 2026 within its -3.0% to +0.5% currency-neutral guidance. That outcome will help show whether the expected 2027 recovery is realistic. See full rankings of all C- rated Health Care stocks inside the Weiss Stock Screener.
--